Utility of the prostest to predict and monitor response to chemotherapy in metastatic Castration-Resistant prostate cancer: A prospective pilot study
Abstract Background Metastatic castration-resistant prostate cancer (mCRPC) treatment has advanced with therapies such as androgen receptor pathway inhibitors (ARPIs), taxane chemotherapies like docetaxel, and novel agents like 177Lu-PSMA. However, predicting patient responses and sequencing therapi...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-025-14549-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!